以亚急性甲状腺炎为首发表现的肢端肥大症1例随访并文献复习

Abstract
Figure/Table
References (20)
Related Citation (3)

Download: PDF (1037 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract The clinical data of one patient of acromegaly with first clinical manifestation as subacute thyroiditis was fully analyzed, and related literatures were reviewed. The patient ignored progressive somatic enlargement and jaw overgrowth weakness for years, and visited different department before endocrinology, until subacute thyroiditis happened, through reviewing the whole story of the patient, and hormone and MRI examination, acromegaly caused by pituitary tumor releasing excess growth hormone was diagnosed. After operation, the appearance and bone were both recovered. Acromegaly is a rare chronic disease which combined with different complications in several systems，and subacute thyroiditis as the first manifestation is rare. After reviewing the literature, growth hormone may play a role in the crosstalk between immune system and neuroendocrine system, which may give new way of knowing acromegaly.

Key words： Acromegaly Subacute thyroiditis Pituitary Growth factor First clinical manifestation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Jia

Cite this article:

LI Jia. Follow-up of 1 case of acromegaly with the first clinical manifestation of subacute thyroiditis and review of the literature[J]. 中国医药导报, 2018, 15(36): 144-147,151.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I36/144

[1] Almalki MH，Chesover AD，Johnson MD，et al. Characterization of management and outcomes of patients with acromegaly in Vancouver over 30 years [J]. Clin Invest Med，2012，135（1）：E27-E33.
[2] Ghazi AA，Amirbaigloo A，Dezfooli AA，et al. Ectopic acr-omegaly due to hormone releasing hormone [J]. Endocrine，2013，43（2）：293-302.
[3] 中华医学会神经外科学分会，中国垂体腺瘤协作组，中华医学会内分泌学分会.中国肢端肥大症诊治指南（2013）[J].中华神经外科杂志，2013，29（10）：975-979.
[4] Colao A，Ferone D，Marzullo P，et al. Systemic complications of acromegaly：epidemiology，pathogenesis，and management [J]. Endocrine Reviews，2004，25（1）：102-152.
[5] Eskildsen PC，Kruse A，Kirkegard C. The pituitary-thyroid-thyroid axis in acromegaly [J]. Horm Metab Res，1988，20（12）：755-757.
[6] Uchoa HB，Lima GA，Correa LL，et al. Prevelence of thyroid diseases in patients with acromegaly：experience of a Brazilian Center [J]. Arq Bras Endocrinol Metabol，2013， 57（9）：685-690.
[7] Katznelon L，Atkinson J，Cook D，et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update [J]. Endocrinol Metab，2011，17（supplement 4）：1-44.
[8] Katznelon L，Laws ER，Melded S，et al. Acromegaly：an endocrine society clinical practice guideline [J]. J Clin Endocrinol Metab，2014，99（11）：3933-3951.
[9] 田丹，岑晶，顾锋.2011年美国内分泌医师学会肢端肥大症诊疗临床实践指南解读[J].中国实用内科杂志，2012，32（10）：764-774.
[10] Gasperi M，Martino E，Manetti L，et al. Prevalence of thyroid diseases in patients with acromegaly：results of an Italian multi-center study [J]. J Endocrinol Invest，2002， 25（3）：240-245.
[11] Reverter JL，Fajardo C，Resmini E，et al. Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? [J]. Plos One，2014，9（8）：e104174.
[12] Kosma W，Agata C，Marek R. Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly-meta-analysis and systematic review [J]. PLoS One，2014， 9（2）：e88787.
[13] Dogansen SC，Selcukbiricik OS，Bilir BE，et al. The higher incidence of autoimmune thyroid disease in prolactinomas than in somatotrophinomas [J]. Growth Horm IGF Res，2016，29（8）：45-49.
[14] Maria DA，Stanis?覥aw TJ，Maria K，et al. Thyroid diseases in patients with acromegaly [J]. Archives of Medical Science，2014，10（4）：837-845.
[15] Hollowell JG，Staehling NW，Flanders WD，et al. Serum TSH，T4，and thyroid antibodies in the United State′s population（1988-1994）：National Health and Nutrition Examination Survey （NANHESⅢ） [J]. J Clin Endocrino Metab，2002，87（32）：489-499.
[16] Ishibashi M，Kuzuya N，Sawada S，et al. Anti-thyroid antibodies in patients with hyperprolactinemia [J]. Endocrinol JPN，1991，38（5）：517-522.
[17] Manavela M，Vigovich C，Danilowicz K，et al. Thyroid autoimmune disorders in patients with acromegaly [J]. Pituitary，2015，18（6）：912.
[18] Smaniotto S，Martins-Neto AA，Dardenne M，et al. Growth hormone is modulator of lymphocyte migration [J]. Neuro Immuno Modulation，2011，18（5）：309-313.
[19] Savino W，Postel-Vinay MC，Smaniotto S，et al. The thymus gland：a target organ for the growth hormone [J]. Scand J Immunol，2002，55（5）：442-452.
[20] Savino W，Smaniotto S，Mendes-da-Cruz DA，et al. Growth hormone modulates migration of thymocytes and peripheral T cells [J]. Ann NY ACAD Sci，2012，1261（1）：49-54.